Compare American International Group Inc (AIG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? American International Group Inc trades at $76.32 (market cap $40.42B), while State Street SPDR S&P Biotech ETF trades at $159.63. The key difference: American International Group Inc pays a 2.59% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, American International Group Inc nearer its low. Which is the better fit depends on your goals.
| AIG | XBI | |
|---|---|---|
Market Cap | $40.42B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $86.59 | $164.28 |
52-Week Low | $71.89 | $86.92 |
Enterprise Value | $48.06B | — |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $77.61, down 1.49% today, with a bearish technical signal but strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.00 exceeding the $1.92 estimate. The company maintains solid profitability with an 11.12% net income margin and a P/E of 14.11, indicating reasonable valuation. Cash flow from operations remains positive at $3.31 billion for 2025, supporting dividend payments of $0.50 per share.
The outlook is mixed; analyst consensus is a Buy with a $89.00 price target, suggesting 14.7% upside, but technical indicators signal near-term caution. Risks include competitive pricing pressure and geopolitical exposures, while opportunities lie in disciplined underwriting and AI integration. Investor sentiment is cautiously optimistic amid steady premium growth and expense control.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
